RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This is a Current Report (Form 8-K) filed by Relmada Therapeutics, Inc. on March 13, 2023, covering the date of the earliest event reported on March 10, 2023. The company is incorporated in Nevada and its common stock trades on the NASDAQ Global Select Market under the symbol RLMD.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific disclosure regarding banking relationships.
Material Changes and Disclosure
Under Item 7.01 (Regulation FD Disclosure), the company announced that it does not hold cash deposits or securities at Silicon Valley Bank. This disclosure was made in the context of the banking sector instability occurring at that time.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general business risks beyond the specific clarification regarding Silicon Valley Bank exposure. The information provided is not deemed "filed" for liability purposes under Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the company's total cash and cash equivalents balance in its most recent 10-Q or 10-K filing to assess overall liquidity.
- Confirm the specific banks where the company holds its deposits to evaluate counterparty risk.
- Review subsequent filings for any updates on the company's financial position or operational status following the March 2023 banking events.